Sanofi Settles 4,000 Zantac Cancer Lawsuits, Faces Delaware Claims

1. Sanofi SA has reached a settlement agreement regarding approximately 4,000 Zantac cancer lawsuits filed in US state courts outside of Delaware.
2. The settlement does not include the 20,000 lawsuits pending in Delaware state court.
3. The financial terms of the settlement have not been disclosed.
4. Sanofi still faces about 70,000 cases in Delaware Superior Court in Wilmington, where a judge is weighing the scientific evidence to support plaintiffs' claims that Zantac causes cancer.
5. The drugmakers, including Sanofi, GSK, Pfizer, and Boehringer Ingelheim, have maintained that there is no evidence Zantac exposed users to harmful levels of the carcinogenic chemical NDMA.
6. Plaintiffs are appealing a 2022 ruling that dismissed about 50,000 similar lawsuits consolidated in federal court in Florida, where the judge concluded that the opinions of the plaintiffs' expert witnesses were not supported by sound science.
7. The lawsuits allege that the companies knew, or should have known, that ranitidine posed a cancer risk and failed to warn consumers.
8. Zantac was originally marketed by a forerunner of GSK and was later sold to Pfizer, Boehringer, and finally to Sanofi.
9. Some manufacturers and pharmacies halted Zantac sales in 2019 after NDMA was detected in some pills, and the US Food and Drug Administration asked manufacturers to pull the drug off the market in 2020.

Please note that the provided information is based on the search results from April 4, 2024.